vs
MERCANTILE BANK CORP（MBWM）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MERCANTILE BANK CORP的季度营收约是MESA LABORATORIES INC的1.0倍（$67.6M vs $65.1M），MERCANTILE BANK CORP净利率更高（33.6% vs 5.6%，领先28.0%），过去两年MERCANTILE BANK CORP的营收复合增速更高（9.1% vs 5.1%）
泰米尔纳德商业银行（TMB）是一家印度银行，总部位于泰米尔纳德邦杜蒂戈林。该行始建于1921年，最初名为纳达尔银行，1962年11月更名为泰米尔纳德商业银行，以拓展纳达尔社群以外的业务。目前该银行在印度全境拥有600家全功能网点、12个区域办事处及各类配套服务中心与自助设施。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
MBWM vs MLAB — 直观对比
营收规模更大
MBWM
是对方的1.0倍
$65.1M
净利率更高
MBWM
高出28.0%
5.6%
两年增速更快
MBWM
近两年复合增速
5.1%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $67.6M | $65.1M |
| 净利润 | $22.7M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | — | 12.2% |
| 净利率 | 33.6% | 5.6% |
| 营收同比 | — | 3.6% |
| 净利润同比 | 16.1% | 316.6% |
| 每股收益（稀释后） | $1.32 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MBWMMLAB
| Q1 26 | $67.6M | — | ||
| Q4 25 | $62.1M | $65.1M | ||
| Q3 25 | $62.4M | $60.7M | ||
| Q2 25 | $60.9M | $59.5M | ||
| Q1 25 | $57.3M | $62.1M | ||
| Q4 24 | $58.5M | $62.8M | ||
| Q3 24 | $58.0M | $57.8M | ||
| Q2 24 | $56.8M | $58.2M |
净利润MBWMMLAB
| Q1 26 | $22.7M | — | ||
| Q4 25 | $22.8M | $3.6M | ||
| Q3 25 | $23.8M | $2.5M | ||
| Q2 25 | $22.6M | $4.7M | ||
| Q1 25 | $19.5M | $-7.1M | ||
| Q4 24 | $19.6M | $-1.7M | ||
| Q3 24 | $19.6M | $3.4M | ||
| Q2 24 | $18.8M | $3.4M |
毛利率MBWMMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% |
营业利润率MBWMMLAB
| Q1 26 | — | — | ||
| Q4 25 | 42.0% | 12.2% | ||
| Q3 25 | 44.0% | 7.8% | ||
| Q2 25 | 42.6% | 5.1% | ||
| Q1 25 | 42.0% | 2.4% | ||
| Q4 24 | 39.7% | 9.2% | ||
| Q3 24 | 42.4% | 6.1% | ||
| Q2 24 | 41.4% | 9.6% |
净利率MBWMMLAB
| Q1 26 | 33.6% | — | ||
| Q4 25 | 36.8% | 5.6% | ||
| Q3 25 | 38.1% | 4.1% | ||
| Q2 25 | 37.1% | 8.0% | ||
| Q1 25 | 34.1% | -11.4% | ||
| Q4 24 | 33.5% | -2.7% | ||
| Q3 24 | 33.8% | 5.9% | ||
| Q2 24 | 33.1% | 5.8% |
每股收益（稀释后）MBWMMLAB
| Q1 26 | $1.32 | — | ||
| Q4 25 | $1.41 | $0.65 | ||
| Q3 25 | $1.46 | $0.45 | ||
| Q2 25 | $1.39 | $0.85 | ||
| Q1 25 | $1.21 | $-1.30 | ||
| Q4 24 | $1.20 | $-0.31 | ||
| Q3 24 | $1.22 | $0.63 | ||
| Q2 24 | $1.17 | $0.62 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $29.0M |
| 总债务越低越好 | $1.5M | $68.4M |
| 股东权益账面价值 | $736.9M | $186.7M |
| 总资产 | $6.9B | $434.8M |
| 负债/权益比越低杠杆越低 | 0.00× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资MBWMMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $29.0M | ||
| Q3 25 | — | $20.4M | ||
| Q2 25 | — | $21.3M | ||
| Q1 25 | — | $27.3M | ||
| Q4 24 | — | $27.3M | ||
| Q3 24 | — | $24.3M | ||
| Q2 24 | — | $28.5M |
总债务MBWMMLAB
| Q1 26 | $1.5M | — | ||
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M |
股东权益MBWMMLAB
| Q1 26 | $736.9M | — | ||
| Q4 25 | $724.9M | $186.7M | ||
| Q3 25 | $657.6M | $178.5M | ||
| Q2 25 | $631.5M | $172.5M | ||
| Q1 25 | $608.3M | $159.8M | ||
| Q4 24 | $584.5M | $155.2M | ||
| Q3 24 | $583.3M | $161.5M | ||
| Q2 24 | $551.2M | $150.7M |
总资产MBWMMLAB
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.8B | $434.8M | ||
| Q3 25 | $6.3B | $430.4M | ||
| Q2 25 | $6.2B | $435.7M | ||
| Q1 25 | $6.1B | $433.3M | ||
| Q4 24 | $6.1B | $433.3M | ||
| Q3 24 | $5.9B | $454.1M | ||
| Q2 24 | $5.6B | $440.4M |
负债/权益比MBWMMLAB
| Q1 26 | 0.00× | — | ||
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流MBWMMLAB
| Q1 26 | — | — | ||
| Q4 25 | $18.0M | $18.8M | ||
| Q3 25 | $23.1M | $8.2M | ||
| Q2 25 | $-7.8M | $1.9M | ||
| Q1 25 | $-3.0M | $12.7M | ||
| Q4 24 | $101.1M | $18.1M | ||
| Q3 24 | $-8.1M | $5.3M | ||
| Q2 24 | $9.1M | $10.7M |
自由现金流MBWMMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | — | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M |
自由现金流率MBWMMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% |
资本支出强度MBWMMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 1.5% |
现金转化率MBWMMLAB
| Q1 26 | — | — | ||
| Q4 25 | 0.79× | 5.17× | ||
| Q3 25 | 0.97× | 3.32× | ||
| Q2 25 | -0.35× | 0.40× | ||
| Q1 25 | -0.15× | — | ||
| Q4 24 | 5.15× | — | ||
| Q3 24 | -0.41× | 1.54× | ||
| Q2 24 | 0.49× | 3.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MBWM
| Net Interest Income | $55.9M | 83% |
| Noninterest Income | $11.7M | 17% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
